Oxford Biodynamics (OBD)

 0.48p
   
  • Change Today:
      0.000p
  • 52 Week High: 9.31p
  • 52 Week Low: 0.45p
  • Currency: UK Pounds
  • Shares Issued: 1,957.58m
  • Volume: 3,860,472
  • Market Cap: £9.30m

Oxford BioDynamics upbeat on publication of EpiSwitch study

By Josh White

Date: Wednesday 05 Feb 2025

LONDON (ShareCast) - (Sharecast News) - Oxford BioDynamics announced the publication of a multi-institutional clinical study on Wednesday, confirming the accuracy of its EpiSwitch Colorectal No-Stool Test (NST) in detecting colorectal cancer and precancerous polyps using a blood sample.
The AIM-traded firm said the study, published in the journal Cancers, reported an 81% accuracy rate for detecting early-stage colorectal cancer and 82% for non-cancerous polyps.

It said the research involved collaboration between Oxford BioDynamics, Norwich Medical School at the University of East Anglia, University Hospitals NHS Trust, and multiple Malaysian hospitals.

Using blood samples from 325 patients, the study identified and validated two eight-marker signatures using the EpiSwitch 3D genomics platform.

It said the test enabled early and accurate detection of colorectal cancer and polyps, offering a potential alternative to conventional screening methods.

Oxford BioDynamics said it was in discussions with potential partners to bring the test into clinical practice.

The company highlighted the potential of EpiSwitch technology in mapping key biomarkers to genetic pathways that contribute to colorectal cancer progression.

"Reliable and non-invasive detection of early stages of colorectal cancer, as well as the polyps, has been the focus of strenuous efforts by a number of big biomarker companies deploying common biomarker modalities," said chief scientific officer Dr Alexandre Akoulitchev.

"To date the results in terms of sensitivity of detection for polyps and positive predictive value for cancer have been disappointing.

"Our own approach and these reported results demonstrate the consistent accuracy of EpiSwitch technology for the most challenging patient stratifications and will allow us to progress our ongoing commercial discussions with third parties."

At 1125 GMT, shares in Oxford BioDynamics were flat at 0.5p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OBD Market Data

Currency UK Pounds
Share Price 0.48p
Change Today 0.000p
% Change 0.00 %
52 Week High 9.31p
52 Week Low 0.45p
Volume 3,860,472
Shares Issued 1,957.58m
Market Cap £9.30m

OBD Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend Not Available
Income Not Available
Growth Not Available

OBD Dividends

No dividends found

Trades for 31-Mar-2025

Time Volume / Share Price
13:03 54,347 @ 0.46p
12:28 32,000 @ 0.49p
12:19 6,333 @ 0.45p
11:38 500,000 @ 0.45p
10:38 2,000,000 @ 0.46p

Top of Page